pdf   xlsx method abbreviations

lung cancer : small cell (SCLC), nivolumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.84 [0.69, 1.02]< 10%1 study (1/-)96.0 %NAnot evaluable crucial-
progression or deaths (PFS) 0.67 [0.56, 0.81]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 2.93 [1.44, 5.95]> 10%1 study (1/-)99.9 %NAnot evaluable non important-

safety endpoints 00

TRAE (any grade) 1.49 [1.06, 2.08]< 10%1 study (1/-)1.0 %NAnot evaluable non important-
TRAE (grade 3-4) 1.59 [0.90, 2.79]< 10%1 study (1/-)5.4 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.98 [0.06, 15.78]< 10%1 study (1/-)50.5 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 20.14 [4.80, 84.52]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons